HSBC Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.6M | Buy |
89,619
+102
| +0.1% | +$34.7K | 0.02% | 644 |
|
|
2025
Q4 | $35.7M | Buy |
89,517
+16,503
| +23% | +$7.3M | 0.02% | 585 |
|
|
2025
Q3 | $33.3M | Sell |
73,014
-8,734
| -11% | -$3.56M | 0.02% | 577 |
|
|
2025
Q2 | $26.6M | Buy |
81,748
+20,483
| +33% | +$5.67M | 0.02% | 621 |
|
|
2025
Q1 | $16.5M | Sell |
61,265
-317
| -0.5% | -$81.5K | 0.01% | 765 |
|
|
2024
Q4 | $14.5M | Buy |
61,582
+4,712
| +8% | +$1.24M | 0.01% | 812 |
|
|
2024
Q3 | $15.6M | Buy |
56,870
+2,715
| +5% | +$707K | 0.01% | 797 |
|
|
2024
Q2 | $13.2M | Sell |
54,155
-19,976
| -27% | -$3.15M | 0.01% | 788 |
|
|
2024
Q1 | $11.1M | Buy |
74,131
+29,932
| +68% | +$4.99M | 0.01% | 850 |
|
|
2023
Q4 | $8.47M | Buy |
44,199
+9,014
| +26% | +$1.54M | 0.01% | 950 |
|
|
2023
Q3 | $6.23M | Buy |
35,185
+4,508
| +15% | +$860K | 0.01% | 1008 |
|
|
2023
Q2 | $5.83M | Sell |
30,677
-8,617
| -22% | -$1.71M | 0.01% | 1000 |
|
|
2023
Q1 | $7.87M | Buy |
39,294
+6,560
| +20% | +$1.38M | 0.01% | 947 |
|
|
2022
Q4 | $7.78M | Sell |
32,734
-2,659
| -8% | -$567K | 0.01% | 1071 |
|
|
2022
Q3 | $7.18M | Sell |
35,393
-14,468
| -29% | -$2.76M | 0.01% | 1037 |
|
|
2022
Q2 | $7.27M | Buy |
49,861
+2,034
| +4% | +$289K | 0.01% | 1036 |
|
|
2022
Q1 | $7.82M | Buy |
47,827
+6,487
| +16% | +$988K | 0.01% | 1011 |
|
|
2021
Q4 | $7.02M | Buy |
41,340
+12,626
| +44% | +$2.35M | 0.01% | 1123 |
|
|
2021
Q3 | $5.35M | Buy |
28,714
+1,004
| +4% | +$188K | 0.01% | 1123 |
|
|
2021
Q2 | $4.68M | Sell |
27,710
-5,210
| -16% | -$763K | 0.01% | 1132 |
|
|
2021
Q1 | $4.62M | Sell |
32,920
-570
| -2% | -$85.8K | 0.01% | 1048 |
|
|
2020
Q4 | $4.36M | Sell |
33,490
-1,185
| -3% | -$158K | 0.01% | 1072 |
|
|
2020
Q3 | $5.06M | Buy |
34,675
+18,154
| +110% | +$2.58M | 0.01% | 946 |
|
|
2020
Q2 | $2.45M | Buy |
16,521
+7,012
| +74% | +$945K | ﹤0.01% | 1109 |
|
|
2020
Q1 | $1.03M | Buy |
9,509
+626
| +7% | +$72.3K | ﹤0.01% | 1441 |
|
|
2019
Q4 | $1.04M | Sell |
8,883
-75,959
| -90% | -$7.57M | ﹤0.01% | 1824 |
|
|
2019
Q3 | $6.82M | Buy |
84,842
+77,872
| +1,117% | +$6.16M | 0.01% | 1035 |
|
|
2019
Q2 | $506K | Sell |
6,970
-1,405
| -17% | -$108K | ﹤0.01% | 2060 |
|
|
2019
Q1 | $782K | Sell |
8,375
-111,705
| -93% | -$9.34M | ﹤0.01% | 1941 |
|
|
2018
Q4 | $8.76M | Buy |
120,080
+109,262
| +1,010% | +$8.4M | 0.02% | 886 |
|
|
2018
Q3 | $946K | Sell |
10,818
-7,628
| -41% | -$767K | ﹤0.01% | 1774 |
|
|
2018
Q2 | $1.82M | Sell |
18,446
-18,894
| -51% | -$1.87M | ﹤0.01% | 1538 |
|
|
2018
Q1 | $4.45M | Buy |
37,340
+27,817
| +292% | +$3.59M | 0.01% | 1150 |
|
|
2017
Q4 | $1.21M | Buy |
+9,523
| New | +$1.2M | ﹤0.01% | 1240 |
|
|
2017
Q3 | – | Sell |
-17,908
| Closed | -$1.43M | – | 2292 |
|
|
2017
Q2 | $1.43M | Buy |
+17,908
| New | +$1.14M | ﹤0.01% | 1358 |
|
|
2016
Q4 | – | Sell |
-10,047
| Closed | -$681K | – | 2720 |
|
|
2016
Q3 | $681K | Buy |
10,047
+151
| +2% | +$10.7K | ﹤0.01% | 1468 |
|
|
2016
Q2 | $549K | Sell |
9,896
-240
| -2% | -$15.1K | ﹤0.01% | 1542 |
|
|
2016
Q1 | $636K | Sell |
10,136
-1,350
| -12% | -$89.8K | ﹤0.01% | 1468 |
|
|
2015
Q4 | $1.08M | Sell |
11,486
-6,963
| -38% | -$646K | ﹤0.01% | 1444 |
|
|
2015
Q3 | $1.48M | Sell |
18,449
-4,942
| -21% | -$549K | ﹤0.01% | 1135 |
|
|
2015
Q2 | $2.8M | Buy |
23,391
+18,473
| +376% | +$2.21M | 0.01% | 988 |
|
|
2015
Q1 | $514K | Sell |
4,918
-363
| -7% | -$36.8K | ﹤0.01% | 1549 |
|
|
2014
Q4 | $512K | Buy |
+5,281
| New | +$489K | ﹤0.01% | 1482 |
|
Other funds holding ALNY
VPM
VCM
HSBC Holdings's ALNY Position: Q1 2026 in Review
HSBC Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 0.11% in Q1 2026, buying an estimated $34.7K and bringing the position to 89,619 shares worth $29.6M. The position accounts for 0.02% of the portfolio, ranked #644.
HSBC Holdings first reported a position in ALNY in Q4 2014 and has held it in 43 quarters since. The position peaked at $35.7M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- HSBC Holdings held 89,619 shares of Alnylam Pharmaceuticals worth $29.6M as of Q1 2026.
- HSBC Holdings bought 102 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $34.7K.
- Alnylam Pharmaceuticals made up 0.02% of HSBC Holdings's portfolio in Q1 2026, its #644 holding.
- HSBC Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 43 quarters since.
- HSBC Holdings's Alnylam Pharmaceuticals position peaked at $35.7M in Q4 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.